Chronic Inducible Urticaria
Patients with chronic inducible urticaria see complete response to briquilimab at 6 weeks
Patients with chronic inducible urticaria experienced partial or complete response to briquilimab in 6 weeks with a favorable safety and tolerability profile, according to an online presentation by Jasper Therapeutics.
Top in allergy/asthma: FDA proposal on oral phenylephrine; Medicaid barriers to care
Following an FDA review that found oral phenylephrine is ineffective in treating nasal congestion, the administration has proposed an order to remove the active ingredient from over-the-counter nasal decongestants.
Chronic inducible urticaria improves in 12 weeks with barzolvolimab
BOSTON — Patients with chronic inducible urticaria saw improvements in itch and wheals with barzolvolimab in 12 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Barzolvolimab achieves complete responses in chronic inducible urticaria
Patients with cold urticaria and symptomatic dermographism experienced clinically meaningful and statistically significant complete responses with barzolvolimab, according to a webinar by Celldex Therapeutics.
Incyte adds to pipeline with acquisition of Escient Pharmaceuticals
Incyte and Escient Pharmaceuticals have entered a definitive agreement under which Incyte will acquire Escient for $750 million, the companies announced in a press release.
Jasper Therapeutics doses first patient in chronic inducible urticaria study
The first patient has been dosed in Jasper Therapeutic’s phase 1b/2a SPOTLIGHT clinical trial of subcutaneous briquilimab for the treatment of chronic inducible urticaria, the company announced in a press release.